semaj83/ctmatch_classification huggingface dataset:
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  X-linked Hypophosphatemia Main 1. 18 years or older 2. Clinical diagnosis of XLH 3. TmP/GFR < 2.0 mg/dL 4. GFR ≥60 mL/min 5. Corrected Ca <10.8 mg/dL 6. A willingness to utilize adequate contraception and not become pregnant[or to have their partner(s) become pregnant] during the study 7. Additional apply Main  Have any sign of active infectious disease or have had an infection requiring treatment with antibiotics within 3-weeks of Screening 2. History of known immunodeficiency 3. Pregnant or lactating females subjects or female planning to be become pregnant during the study 4. Receipt of a live (attenuated) vaccine (except for influenza vaccines) within 3-months of Screening, and/or during the study 5. Use of pharmacologic vitamin D metabolite or its analog, phosphate, calcimimetics, and ingestion of aluminum hydroxide antacids within 10-days prior to Screening and/or dosing 6. Use of any supplement containing phosphate, calcium and/or vitamin D within 10-days prior to Screening and/or dosing 7. Condition which could present a concern for either the subject's safety or difficulty with data interpretation 8. Additional apply
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 21.0-70.0,  Pulmonary Disease, Chronic Obstructive A subject will be eligible for in this study only if all of the following apply All volunteers must be aged between 21 to 70 years inclusive and be competent to understand and give informed consent All female volunteers of child bearing potential must have provided a negative pregnancy test before and prior to any HRCT scan Body weight < 120 kg and BMI within the range 18 kg/m2 (inclusive) Capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the consent form Available to complete the study Subject will then be included only if they fulfil all for the following relevant cohort Healthy: Cohort Healthy as determined by a responsible and experienced physician, based on a medical evaluation including medical history and physical. A subject with a clinical abnormality or parameters outside the reference range for the population being studied may be included if the Investigator agrees that the finding is unlikely to introduce additional risk factors and will not interfere with the study procedures Non-smokers (never smoked or not smoking for >12 months with <1 pack year history) (Pack years = (cigarettes per day smoked/20) x number of years smoked))  A subject will not be eligible for in this study if any of the following apply As a result of the medical interview, physical examination or screening investigations, the physician responsible considers the volunteer unfit for the study Any pregnant female Volunteers who have a past or present disease, which as judged by the Investigator, may affect subject safety or influence the outcome of the study The subject has received an investigational drug or participated in any other research trial within 30 days or five half-lives, or twice the duration of the biological effect of any drug (whichever is longer) The subject that has both asthma and COPD Previous in a research and/or medical protocol involving nuclear medicine Any Radiological investigations with significant radiation burden (a significant radiation burden being defined as ICRP category IIb or above: No more than 10 mSv in addition to natural background radiation, in the previous 3 years including the dose from this study) The subject has a history of alcohol or drug abuse The subject has had a respiratory tract infection within four weeks of the start of the study
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 20.0-999.0,  Ankylosing Spondylitis Rheumatoid Arthritis Patients with rheumatoid arthritis or ankylosing spondylitis  Patients with mental illness which interfered with questionaire answering
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Chronic Kidney Disease Male or female CKD patients > 18 years old Patients should be willing and able to provide written informed consent and HIPAA authorization to participate in study Chronic kidney disease Stage 3 or 4 per K-DOQI Guidelines: estimated glomerular filtration rate (eGFR) of 15-60 ml/.min/1.73m2 by using modified MDRD equation Serum phosphorus >4.6 mg/dl or plasma intact PTH (iPTH) level above 65 pg/ml or tubular reabsorption of phosphorus (TRP) <80% A negative pregnancy test prior to enrollment in female patients, unless the patient is 2 years postmenopausal, or has had a documented tubal ligation or total hysterectomy Patients need to be off any phosphorus binders for 4 weeks prior to screening Stable dose of vitamin D products for 4 weeks in patients receiving such agents. Dose changes in patients receiving stable and initiation of vitamin D products in patients previously not treated will not be permitted during study  Women who are pregnant, capable of becoming pregnant and not participating in an acceptable form of birth control, or who are breast feeding Patients currently participating in a clinical trial with another investigational drug or device or who have receiving an investigational drug or device within 30 days of enrollment in this study Major surgery within 2 month prior to enrollment in study or planned surgery while the patient is in the study, other than dialysis vascular access surgery Presence of coronary stents, artificial heart valves or pacemakers, and history of CABG Patients with active infections requiring ongoing treatment Patients who have had a malignancy (except for non-melanoma cancer of the skin) unless the patient has received curative treatment and has been disease free for >2 years Patient who the Investigator determines has a medical status that would preclude the patient's participation in the study Patients on hemodialysis (HD) or peritoneal dialysis (PD) Patients with a functional renal transplant Patients with allergies to study drugs
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 18.0-79.0,  Anemia Kidney Disease Key to 79 years of age, inclusive Chronic Kidney Disease (eGFR <60 mL/min), not yet on dialysis Hemoglobin (Hgb) ≤ 10.5 g/dL TSAT ≥ 20% Ferritin ≥ 50 ng/mL Key  BMI >42 Red blood cell transfusion within 12 weeks Androgen therapy within the previous 21 days prior to study dosing Therapy with any approved or experimental erythropoiesis stimulating agent (ESA) within the 11 weeks prior to the Screening visit Subjects meeting the of ESA resistance within the previous 4 months Individual doses of intravenous iron of greater than 250 mg within the past 21 days AST or ALT >1.8x ULN Alkaline phosphatase >2x ULN Total bilirubin >1.5x ULN Uncontrolled hypertension
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 18.0-65.0,  Obesity Vitamin D Deficiency Adult female obese patients undergoing either Roux-en Y gastric bypass or sleeve gastrectomy at The Methodist Hospital may participate in the study. Obese patients with a body mass index (BMI) > 40 or BMI >35 with a co-morbidity will be eligible. -  Subjects will be excluded if they have evidence of vitamin D deficiency (< 20 ng/mL), hypercalcemia (calcium > 2.63 mmol/L), hypocalcemia (calcium < 1.75 mmol/L), renal insufficiency (GFR < 50 ml/min), or a history of primary hyperparathyroidism or renal tubular acidosis.Participants will be excluded if they take medications that interfere with vitamin D metabolism, have significant sun exposure, plan to travel to sunny climates during the study, or a history of hypercalcemia. -
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 19.0-45.0,  Healthy Healthy volunteers, 19 years of age  abnormal urinalysis-presence of hematuria, proteinuria, or leukocyturia pregnancy or breast-feeding Medical conditions impacting phosphate metabolism-primary hyperparathyroidism; gastrointestinal malabsorption disorders such as Crohn's Disease, ulcerative colitis, celiac disease, or liver dysfunction; hyper or hypothyroidism; irregular menses for female subjects Body Mass Index (BMI) ≥ 30 g/m2 since obesity is independently associated with impaired phosphorus metabolism Medications known to affect phosphorus metabolism current use of phosphorus supplements, high-dose or activated vitamin D compounds, regular antacid or laxative use, anticonvulsants Hyper or hypophosphatemia (≥ 4.6 mg/dl or ≤ 2.5 mg/dl respectively), hyper or hypocalcemia (≥ 10.6 or ≤ 8.5 mg/dl respectively), or severe anemia (hemoglobin < 8 g/dl for women and < 9 g/dl for men)
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 40.0-70.0,  Bone Health in Perimenopausal Women They were required to have reduced bone density but no evidence of osteoporosis or osteopenia by Dual-emission X-ray absorptiometry (DEXA) scan (T ≥ -1.0 in the lumbar spine) Perimenopausal women : aged 40-70  Women with a body mass index (BMI) >30 kg/m2 or who were being treated with estrogens, corticosteroids, or bisphosphonates, or who had significant illness affecting bone metabolism were excluded
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 45.0-60.0,  Perimenopause Perimenopausal women aged 45 or more Women who have multiple joint or muscle pain for at least 3 months (at least two sites out of upper and lower extremities or axial)  Rheumatoid arthritis, ankylosing spondylitis, rheumatic polymyalgia, Inflammatory myopathy pregnancy History of hysterectomy or bilateral oophorectomy Vasomotor symptoms History of surgery of musculoskeletal system History of cancer Abnormalities of thyroid function Focal neurologic deficit Smoking within 1 year Uncontrolled hypertension
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 18.0-80.0,  Vitamin D Deficiency Chronic Pain Syndrome Inflammatory Response We enrolled patients suffering from chronic musculo-skeletal pain (low back pain, fibromyalgia, chronic widespread pain) at least 6 months  Patients with low compliance Allergy for vit D
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 25.0-65.0,  Vitamin D Deficiency Serum vitamin D below 75 nmol/L Men and female 65 years of age Born in Middle East or Africa, living in Umeå district  Hypersensitive to Cholecalciferol, cocos oil, palm kernel or rubber Serum D3 equal to or above75 nmol/L Hypercalcemia Renal insufficiency History of Kidney Calculi Nephrocalcinosis History of sarcoidosis and other Granulomatous Diseases Known malignancy Ongoing treatment with phenytoin, barbiturates, rifampicin, isoniazid Ongoing treatment with cardiac glycosides
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 0.75-1.25,  Vitamin D Deficiency Infants between 9-12 months old in Tipat Chalav and Kupat Holim Clalit in Beitar Illit undergoing a blood draw for CBC at one year of age  Parents that refuse to participate in this study, infants with any diagnosed chronic disease, and preterm infants less than 34 weeks
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 18.0-70.0,  Traumatic Brain Injury FOR TBI To be included, TBI patients must meet all of the following Between 18 and 70 years of age Had head injury within the previous 30 days Had a moderate TBI classified as GCS 9-12 or a mild TBI classified as GCS 13-15 at the first ER or other medical examination. If LOC existed, it may not have lasted more than 24 hours. If PTA existed it may not be more than 7 days Admitted to an inpatient unit, ED, and/or evaluated in a doctors' office because of head trauma Injury occurred less than 30 (plus 5) days before enrollment Willingness to provide permission to allow release of medical records related to these injuries. FOR Healthy volunteers will be eligible for enrollment if they meet the following requirements Between 18 and 70 years of age Determined to be healthy at the time of screening No known previous TBI, even mild (characterized as GCS >13, PTA < 1 day LOC < 30 min) FOR NON-TBI Non-TBI trauma controls will be eligible for enrollment if they meet the following  FOR ALL STUDY Study participants will be excluded from the study if he/she has one or more of the following Are not able to read and understand English to complete outcome assessments and neurological scales Progressive or unstable disease of any body system including cardiovascular, pulmonary, gastrointestinal, central nervous system, psychiatric, endocrine, hematologic, renal, or immunologic disorders Alcohol dependence/substance abuse history within the past 5 years Known acute and chronic inflammatory disease (i.e. rheumatoid arthritis, systemic lupus erythematosus, hepatitis, cirrhosis, sepsis, severe periodontosis or HIV infection or AIDS Clinically significant abnormal ECG, or acute myocardial infarction within last 3 months Ischemic or hemorrhagic stroke within last 3 months History of diabetes Currently undergoing evaluation or treatment for chronic illness or presenting with symptoms suggestive of undiagnosed disorders Pregnant or lactating women
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Ataxia Patients with acute pulmonary thromboembolism or acute deep venous thrombosis Fondaparinux injection must be prescribed for the first time  Not applicable
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 18.0-70.0,  Vitamin D Deficiency All patients with Vitamin D level less than 20 ng/dl  Patients who have received vitamin D injection in last 03 months Patients with hypercalcemia (corrected calcium > 10.6 mg/dl) Known Malignancy Known case of CLD or serum ALT > 3 times ULN Patients with creatinine > 2.0 mg/dl
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 2.0-999.0,  Aplastic Anemia Short age-adjusted telomere length in the first percentile and/or a mutation in telomerase genes 2. One or more of the following cytopenia(s) Anemia 1. Symptomatic anemia with a hemoglobin < 9.5 g/dL or red cell transfusion requirements > 2 units/month for at least 2 months 2. Reticulocyte count < 60,000 /microL Thrombocytopenia 1. Platelet count < 30,000 /microL or < 50,000 /microL associated with bleeding 2. Decreased megakaryocytic precursors in the bone marrow Neutropenia 1. Absolute neutrophil count < 1,000 /microL OR 3. Idiopathic pulmonary fibrosis diagnosed by either a lung biopsy of high resolution computed tomography scan of the chest according to guidelines from the American Thoracic Society and European Respiratory Society 4. Age greater than or equal to 2 years 5. Weight > 12 kg  Moribund status or concurrent hepatic, renal, cardiac, neurologic, pulmonary, infectious, or metabolic disease of such severity that it would preclude the patient s ability to tolerate protocol therapy, or that death within 30 days is likely 2. Potential subjects with cancer who are on active chemotherapeutic treatment 3. Current pregnancy, or unwillingness to avoid pregnancy if of childbearing potential 4. Not able to understand the investigational nature of the study or give informed consent or does not have a legally authorized representative or surrogate that can provide informed consent
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 18.0-75.0,  Sub-optimal Vitamin D Status Bone Disease Diabetic Nephropathy Clinical diagnoses of diabetes (type 1 or 2) and stage 2-4 chronic kidney disease (glomerular filtration rate: 15-89 ml/min/1.73m2)  Patients with co-morbid conditions known to affect vitamin D metabolism including gastrointestinal, liver, rheumatoid or bone disorders (e.g. hyperthyroidism, untreated celiac disease, cancer, Paget's disease, sarcoidosis, malabsorption, etc). Individuals with severe, permanent vision impairment will be excluded as this will preclude them from reading supplement labels accurately and safely. Pregnant women will be excluded as DXA scans are not recommended during pregnancy. Patients weighing >136kg will be excluded as the DXA table cannot accommodate this weight Patients on drug therapy known to interfere with vitamin D (e.g. oral glucocorticoids, cholestyramine, colestipol, mineral oil, Orlistat, digoxin, antacids) Patients with stage 5 CKD (GFR <15ml/min/1.73m2), receiving dialysis or on kidney transplant list Patients with pre-existing hypercalcemia (>2.75mmol/l), hyperphosphatemia (>2.0mmol/l), severe hyperparathyroidism (PTH >600pg/ml), and serum 25(OH)D >200nmol/l Patients with serum 25(OH)D <37.5nmol/l at time of study entry/screening to control for correction of vitamin D deficiency